title: [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
abstract: BACKGROUND
  We investigated the clinical usefulness of free to total serum prostate specific antigen (PSA) ratio (F/T ratio) in order to improve the specificity of total PSA measurement for detecting prostate cancer.
  
  
  METHODS
  In this study 129 patients with total PSA level 4-20 ng/ml underwent transrectal ultrasound guided sextant biopsy. Serum samples were assessed for total PSA, free PSA and the F/T ratio calculated. All patients were pathologically diagnosed as benign prostatic hyperplasia or prostate cancer.
  
  
  RESULTS
  Of 129 patients 21 had prostate carcinoma (PCa) and 108 had benign prostatic hyperplasia (BPH) from the results of prostate biopsies. The mean of total PSA were not significantly different between men with PCa and with BPH. The mean of free PSA for PCa was significantly lower than that for BPH (p = 0.043). Furthermore, the mean of F/T ratio was significantly different between PCa and BPH group (p = 0.0014). The F/T ratio had a higher specificity than total PSA at all levels of sensitivity in detecting prostate cancers. Sensitivity, specificity and accuracy for cancer detection at a cut off 0.12 was 90.4%, 51.8% and 58.1%, respectively. Also, free PSA was as useful as F/T ratio for cancer detection when analyzed in receiver operating characteristic curves analysis. When determined the cut off number of free PSA at 0.78 ng/ml, the sensitivity, specificity and accuracy for cancer detection were 61.9%, 66.7% and 65.9%, respectively.
  
  
  CONCLUSIONS
  This study indicated that the F/T ratio and free PSA could improve the specificity without impairing the sensitivity for detecting PCa in patients with 4-20 ng/ml of total PSA.
authors.affiliation: Department of Urology, Yokohama City University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Ohuchi
authors.forename: K
authors.initials: K
authors.lastname: Mikata
authors.forename: Y
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: J
authors.initials: J
authors.lastname: Ohta
authors.forename: Y
authors.initials: Y
authors.lastname: Osada
authors.forename: H
authors.initials: H
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Yao
authors.forename: M
authors.initials: M
authors.lastname: Takeda
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.forename: S
authors.initials: S
authors.lastname: Jinza
authors.forename: T
authors.initials: T
authors.lastname: Asakura
authors.forename: T
authors.initials: T
authors.lastname: Ebato
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen